Belite Bio, Inc.(BLTE)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

BLTE Belite Bio, Inc.

已收盘 12-16 16:00:00 EST

149.13

+6.60

+4.63%

盘后149.13

+0.000.00%

19:10 EST

最高149.27	最低141.00	成交量14.43万
今开141.14	昨收142.53	日振幅5.80%
总市值55.95亿	流通市值29.77亿	总股本3,751万
成交额2,102万	换手率0.72%	流通股本1,996万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"BLTE","market":"US","secType":"STK","nameCN":"Belite Bio, Inc.","latestPrice":149.13,"timestamp":1765918800000,"preClose":142.53,"halted":0,"volume":144304,"hourTrading":{"tag":"盘后","latestPrice":149.13,"preClose":149.13,"latestTime":"19:10 EST","volume":595,"amount":88851.14,"timestamp":1765930253584},"delay":0,"floatShares":19963600,"shares":37514630,"eps":-1.929025,"marketStatus":"已收盘","change":6.6,"latestTime":"12-16 16:00:00 EST","open":141.14,"high":149.27,"low":141,"amount":21023392.89888,"amplitude":0.058023,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.929025,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1765962000000},"marketStatusCode":5,"adr":0,"adrRate":1,"listingDate":1651204800000,"exchange":"NASDAQ","adjPreClose":142.53,"preHourTrading":{"tag":"盘前","latestPrice":144.38,"preClose":142.53,"latestTime":"08:18 EST","volume":345,"amount":49456.89885,"timestamp":1765891111170},"postHourTrading":{"tag":"盘后","latestPrice":149.13,"preClose":149.13,"latestTime":"19:10 EST","volume":595,"amount":88851.14,"timestamp":1765930253584},"volumeRatio":0.553149},"requestUrl":"/m/hq/s/BLTE","defaultTab":"news","newsList":[{"id":"1192110803","title":"Belite Bio宣布以3.5亿美元定价的承销公开发行美国存托股份","url":"https://stock-news.laohu8.com/highlight/detail?id=1192110803","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1192110803?lang=zh_cn&edition=full","pubTime":"2025-12-02 11:38","pubTimestamp":1764646705,"startTime":"0","endTime":"0","summary":"Belite Bio宣布以3.5亿美元定价的承销公开发行美国存托股份","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BLTE","BK4007"],"gpt_icon":0},{"id":"1168494999","title":"曾被视为无法治愈疾病患者的新希望：Belite Bio公布针对青少年Stargardt病的关键全球第三阶段Dragon试验Tinlarebant的积极初步结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1168494999","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1168494999?lang=zh_cn&edition=full","pubTime":"2025-12-01 19:01","pubTimestamp":1764586886,"startTime":"0","endTime":"0","summary":"曾被视为无法治愈疾病患者的新希望：Belite Bio公布针对青少年Stargardt病的关键全球第三阶段Dragon试验Tinlarebant的积极初步结果","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BLTE"],"gpt_icon":0},{"id":"1181287053","title":"Belite Bio宣布英国MHRA同意Tinlarebant治疗Stargardt病的有条件市场授权","url":"https://stock-news.laohu8.com/highlight/detail?id=1181287053","media":"投资观察","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1181287053?lang=zh_cn&edition=full","pubTime":"2025-11-20 00:21","pubTimestamp":1763569310,"startTime":"0","endTime":"0","summary":"11月2日 - Belite Bio Inc.宣布，英国药品和健康产品监管局（MHRA）已同意其基于中期分析结果提出的有条件市场授权申请，以使用Tinlarebant治疗Stargardt病。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BLTE"],"gpt_icon":0},{"id":"1183806485","title":"异动解读 | Belite Bio盘中大涨5.43%，分析师上调目标价至140美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1183806485","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1183806485?lang=zh_cn&edition=full","pubTime":"2025-11-12 22:34","pubTimestamp":1762958079,"startTime":"0","endTime":"0","summary":"11月12日，生物科技公司Belite Bio(股票代码:BLTE)股价盘中大涨5.43%，引发市场关注。\n\n消息面上，投资银行Maxim Group将Belite Bio的目标价从110美元大幅上调至140美元。分析师的看好态度显然提振了投资者信心，推动公司股价上涨。\n\nBelite Bio是一家专注于开发用于治疗眼科和代谢性疾病的新型疗法的临床阶段生物制药公司。目标价的上调表明分析师看好公司的研发管线和未来发展前景。不过，投资者仍需关注该公司的临床试验进展和财务状况等基本面因素。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["BLTE"],"gpt_icon":0},{"id":"2580764702","title":"Belite Bio Inc盘中异动 早盘股价大涨5.21%","url":"https://stock-news.laohu8.com/highlight/detail?id=2580764702","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580764702?lang=zh_cn&edition=full","pubTime":"2025-11-03 22:39","pubTimestamp":1762180757,"startTime":"0","endTime":"0","summary":"北京时间2025年11月03日22时39分，Belite Bio Inc股票出现异动，股价快速上涨5.21%。截至发稿，该股报111.42美元/股，成交量1.1266万股，换手率0.03%，振幅3.48%。Belite Bio Inc股票所在的生物技术行业中，整体跌幅为0.05%。其相关个股中，Phio Pharmaceuticals Corp.、Tharimmune, Inc.、Terns Pharmaceuticals, Inc.涨幅较大，Phio Pharmaceuticals Corp.、Tharimmune, Inc.、Biodexa Pharmaceuticals Plc较为活跃，换手率分别为1527.64%、375.62%、346.04%，振幅较大的相关个股有Ethzilla Corporation C/Wts 06/11/2025、Tharimmune, Inc.、Psyence Biomedical Ltd C/Wts 25/01/2029，振幅分别为63.35%、61.36%、52.07%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251103223918a485690b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251103223918a485690b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","BLTE"],"gpt_icon":0},{"id":"1186565995","title":"Belite Bio宣布英国药品和医疗产品监管局同意根据Tinlarebant治疗Stargardt病的中期分析结果申请有条件市场授权","url":"https://stock-news.laohu8.com/highlight/detail?id=1186565995","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1186565995?lang=zh_cn&edition=full","pubTime":"2025-11-02 22:01","pubTimestamp":1762092073,"startTime":"0","endTime":"0","summary":"Belite Bio宣布英国药品和医疗产品监管局同意根据Tinlarebant治疗Stargardt病的中期分析结果申请有条件市场授权","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BLTE","BK4007"],"gpt_icon":0},{"id":"1133872821","title":"Belite Bio宣布中国NMPA同意Tinlarebant治疗Stargardt病的新药申请，并优先审查","url":"https://stock-news.laohu8.com/highlight/detail?id=1133872821","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1133872821?lang=zh_cn&edition=full","pubTime":"2025-10-15 20:01","pubTimestamp":1760529683,"startTime":"0","endTime":"0","summary":"Belite Bio宣布，中国国家药品监督管理局（NMPA）已同意其针对Tinlarebant治疗Stargardt病的新药申请，并将根据中期分析结果进行优先审查。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BLTE","BK4007"],"gpt_icon":0},{"id":"2567217619","title":"Belite Bio Inc盘中异动 大幅拉升5.43%","url":"https://stock-news.laohu8.com/highlight/detail?id=2567217619","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2567217619?lang=zh_cn&edition=full","pubTime":"2025-09-15 22:37","pubTimestamp":1757947030,"startTime":"0","endTime":"0","summary":"北京时间2025年09月15日22时37分，Belite Bio Inc股票出现波动，股价大幅拉升5.43%。截至发稿，该股报73.25美元/股，成交量1.4336万股，换手率0.04%，振幅4.46%。Belite Bio Inc股票所在的生物技术行业中，整体跌幅为0.16%。其相关个股中，Monte Rosa Therapeutics, Inc.、冠科美博、C4 Therapeutics, Inc.涨幅较大，Salarius Pharmaceuticals, Inc.、Nucana Plc、Atyr Pharma, Inc.较为活跃，换手率分别为545.73%、95.70%、83.75%，振幅较大的相关个股有Psyence Biomedical Ltd C/Wts 25/01/2029、Lakeshore Biopharma Co Ltd C/Wts 15/03/2028 、Monte Rosa Therapeutics, Inc.，振幅分别为46.37%、30.57%、26.20%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250915223710a7227089&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250915223710a7227089&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","BLTE"],"gpt_icon":0},{"id":"1121342685","title":"Belite Bio宣布完成Dragon试验，这是一项为期两年的口服Tinlarebant治疗斯塔加特病的三期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1121342685","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1121342685?lang=zh_cn&edition=full","pubTime":"2025-09-12 20:00","pubTimestamp":1757678418,"startTime":"0","endTime":"0","summary":"Belite Bio宣布完成Dragon试验，这是一项为期两年的口服Tinlarebant治疗斯塔加特病的三期临床试验","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BLTE"],"gpt_icon":0},{"id":"1185999912","title":"Belite Bio宣布获得由知名医疗投资者提供的高达2.75亿美元增额私募融资","url":"https://stock-news.laohu8.com/highlight/detail?id=1185999912","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1185999912?lang=zh_cn&edition=full","pubTime":"2025-09-08 20:01","pubTimestamp":1757332879,"startTime":"0","endTime":"0","summary":"Belite Bio宣布获得由知名医疗投资者提供的高达2.75亿美元增额私募融资","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BLTE","BK4007"],"gpt_icon":0},{"id":"2558665689","title":"Belite Bio Inc盘中异动 快速上涨5.26%报73.56美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2558665689","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2558665689?lang=zh_cn&edition=full","pubTime":"2025-08-11 21:33","pubTimestamp":1754919187,"startTime":"0","endTime":"0","summary":"北京时间2025年08月11日21时33分，Belite Bio Inc股票出现异动，股价大幅上涨5.26%。截至发稿，该股报73.56美元/股，成交量5308股，换手率0.02%，振幅6.74%。Belite Bio Inc股票所在的生物技术行业中，整体跌幅为0.32%。其相关个股中，Equillium, Inc.、Entero Therapeutics Inc.、Bioxcel Therapeutics, Inc.涨幅较大，Entero Therapeutics Inc.、Equillium, Inc.、Io Biotech, Inc.较为活跃，换手率分别为1794.69%、220.75%、77.19%，振幅较大的相关个股有Equillium, Inc.、Entero Therapeutics Inc.、Io Biotech, Inc.，振幅分别为48.47%、33.16%、11.88%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250811213308a48216f1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250811213308a48216f1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BLTE","BK4007"],"gpt_icon":0},{"id":"2557564988","title":"Belite Bio Inc盘中异动 股价大涨5.16%报71.50美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2557564988","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2557564988?lang=zh_cn&edition=full","pubTime":"2025-08-07 22:25","pubTimestamp":1754576732,"startTime":"0","endTime":"0","summary":"北京时间2025年08月07日22时25分，Belite Bio Inc股票出现波动，股价急速上涨5.16%。截至发稿，该股报71.50美元/股，成交量1.4156万股，换手率0.04%，振幅4.65%。Belite Bio Inc股票所在的生物技术行业中，整体跌幅为0.33%。其相关个股中，60 Degrees Pharmaceuticals Inc C/Wts 12/07/2028 、Omniab Inc C/Wts 、Cingulate Inc C/Wts 10/12/2026 涨幅较大，Palisade Bio, Inc.、Bioxcel Therapeutics, Inc.、Processa Pharmaceuticals, Inc.较为活跃，换手率分别为1617.28%、118.62%、80.19%，振幅较大的相关个股有Palisade Bio, Inc.、Briacell Therapeutics Corp C/Wts 26/02/2026、Rocket Pharmaceuticals Inc C/Wts 02/09/2026 ，振幅分别为92.00%、39.49%、34.85%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250807222532a6d90f25&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250807222532a6d90f25&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","BLTE"],"gpt_icon":0},{"id":"2557336244","title":"Belite Bio Inc盘中异动 临近收盘急速上涨5.14%","url":"https://stock-news.laohu8.com/highlight/detail?id=2557336244","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2557336244?lang=zh_cn&edition=full","pubTime":"2025-08-05 03:40","pubTimestamp":1754336456,"startTime":"0","endTime":"0","summary":"北京时间2025年08月05日03时40分，Belite Bio Inc股票出现异动，股价急速拉升5.14%。Belite Bio Inc股票所在的生物技术行业中，整体涨幅为1.61%。Belite Bio Inc公司简介：Belite Bio Inc是一家临床阶段的生物制药药物开发公司，专注于针对不可治疗眼病的新型疗法，包括视网膜变性，如萎缩性年龄相关性黄斑变性和常染色体隐性Stargardt病，这两种疾病都将逐渐导致永久性失明；以及代谢性疾病，如非酒精性脂肪性肝病、非酒精性脂肪性肝炎、2型糖尿病和痛风。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025080503405697338f3c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025080503405697338f3c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BLTE","BK4007"],"gpt_icon":0},{"id":"2550365401","title":"Belite Bio Inc盘中异动 急速拉升5.12%报63.20美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2550365401","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550365401?lang=zh_cn&edition=full","pubTime":"2025-07-10 00:25","pubTimestamp":1752078306,"startTime":"0","endTime":"0","summary":"北京时间2025年07月10日00时25分，Belite Bio Inc股票出现波动，股价快速拉升5.12%。截至发稿，该股报63.20美元/股，成交量2.2452万股，换手率0.07%，振幅6.56%。Belite Bio Inc股票所在的生物技术行业中，整体涨幅为1.12%。其相关个股中，Calidi Biotherapeutics, Inc.、Lixte Biotechnology Holdings  Inc C/Wts 30/11/2025 、60 Degrees Pharmaceuticals Inc C/Wts 12/07/2028 涨幅较大，Calidi Biotherapeutics, Inc.、Kazia Therapeutics Limited、Mustang Bio, Inc.较为活跃，换手率分别为1593.20%、740.81%、621.70%，振幅较大的相关个股有Calidi Biotherapeutics, Inc.、Lixte Biotechnology Holdings  Inc C/Wts 30/11/2025 、Nucana Plc，振幅分别为253.73%、154.98%、130.04%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250710002507a69fc9e4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250710002507a69fc9e4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BLTE","BK4007"],"gpt_icon":0},{"id":"2518210273","title":"Belite Bio Inc盘中异动 早盘大幅上涨6.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=2518210273","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518210273?lang=zh_cn&edition=full","pubTime":"2025-03-10 21:31","pubTimestamp":1741613476,"startTime":"0","endTime":"0","summary":"北京时间2025年03月10日21时31分，Belite Bio Inc股票出现波动，股价大幅上涨6.03%。截至发稿，该股报67.00美元/股，成交量1162股，换手率0.00%，振幅0.00%。Belite Bio Inc股票所在的生物技术行业中，整体跌幅为0.59%。Belite Bio Inc公司简介：Belite Bio Inc是一家临床阶段的生物制药药物开发公司，专注于针对涉及视网膜变性的不可治疗眼病的新疗法，如萎缩性年龄相关性黄斑变性和常染色体隐性Stargardt病或STGD1，这两种疾病都将逐渐导致永久性失明。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310213117964035a0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310213117964035a0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BLTE","BK4007"],"gpt_icon":0},{"id":"2517602164","title":"Belite Bio Inc盘中异动 快速拉升5.30%报60.20美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517602164","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517602164?lang=zh_cn&edition=full","pubTime":"2025-03-05 01:53","pubTimestamp":1741110821,"startTime":"0","endTime":"0","summary":"北京时间2025年03月05日01时53分，Belite Bio Inc股票出现波动，股价大幅拉升5.30%。截至发稿，该股报60.20美元/股，成交量2.2093万股，换手率0.07%，振幅6.12%。Belite Bio Inc股票所在的生物技术行业中，整体跌幅为0.28%。Belite Bio Inc公司简介：Belite Bio Inc是一家临床阶段的生物制药药物开发公司，专注于针对涉及视网膜变性的不可治疗眼病的新疗法，如萎缩性年龄相关性黄斑变性和常染色体隐性Stargardt病或STGD1，这两种疾病都将逐渐导致永久性失明。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305015342989bdd5a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305015342989bdd5a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","BLTE"],"gpt_icon":0},{"id":"2516652728","title":"Belite Bio Inc盘中异动 下午盘快速拉升5.23%报60.19美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2516652728","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516652728?lang=zh_cn&edition=full","pubTime":"2025-03-04 02:49","pubTimestamp":1741027758,"startTime":"0","endTime":"0","summary":"北京时间2025年03月04日02时49分，Belite Bio Inc股票出现波动，股价急速拉升5.23%。截至发稿，该股报60.19美元/股，成交量3.8615万股，换手率0.12%，振幅4.15%。Belite Bio Inc股票所在的生物技术行业中，整体涨幅为0.61%。Belite Bio Inc公司简介：Belite Bio Inc是一家临床阶段的生物制药药物开发公司，专注于针对涉及视网膜变性的不可治疗眼病的新疗法，如萎缩性年龄相关性黄斑变性和常染色体隐性Stargardt病或STGD1，这两种疾病都将逐渐导致永久性失明。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304024918989a496c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304024918989a496c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BLTE","BK4007"],"gpt_icon":0},{"id":"2516374952","title":"Belite Bio Inc盘中异动 临近午盘股价大跌5.11%报55.29美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2516374952","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516374952?lang=zh_cn&edition=full","pubTime":"2025-03-01 00:46","pubTimestamp":1740761160,"startTime":"0","endTime":"0","summary":"北京时间2025年03月01日00时46分，Belite Bio Inc股票出现波动，股价大幅跳水5.11%。截至发稿，该股报55.29美元/股，成交量3.3522万股，换手率0.11%，振幅4.96%。Belite Bio Inc股票所在的生物技术行业中，整体涨幅为0.31%。Belite Bio Inc公司简介：Belite Bio Inc是一家临床阶段的生物制药药物开发公司，专注于针对涉及视网膜变性的不可治疗眼病的新疗法，如萎缩性年龄相关性黄斑变性和常染色体隐性Stargardt病或STGD1，这两种疾病都将逐渐导致永久性失明。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250301004601abe10a5e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250301004601abe10a5e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","BLTE"],"gpt_icon":0},{"id":"2514638304","title":"Belite Bio Inc盘中异动 股价大涨5.32%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514638304","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514638304?lang=zh_cn&edition=full","pubTime":"2025-02-27 22:32","pubTimestamp":1740666769,"startTime":"0","endTime":"0","summary":"北京时间2025年02月27日22时32分，Belite Bio Inc股票出现波动，股价大幅上涨5.32%。截至发稿，该股报58.45美元/股，成交量1.5494万股，换手率0.05%，振幅1.80%。Belite Bio Inc股票所在的生物技术行业中，整体涨幅为0.31%。Belite Bio Inc公司简介：Belite Bio Inc是一家临床阶段的生物制药药物开发公司，专注于针对涉及视网膜变性的不可治疗眼病的新疗法，如萎缩性年龄相关性黄斑变性和常染色体隐性Stargardt病或STGD1，这两种疾病都将逐渐导致永久性失明。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227223249abdf6ef6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227223249abdf6ef6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BLTE","BK4007"],"gpt_icon":0},{"id":"2510323337","title":"Belite Bio Inc盘中异动 大幅上涨5.95%报57.00美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2510323337","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2510323337?lang=zh_cn&edition=full","pubTime":"2025-02-12 01:21","pubTimestamp":1739294494,"startTime":"0","endTime":"0","summary":"北京时间2025年02月12日01时21分，Belite Bio Inc股票出现波动，股价快速上涨5.95%。截至发稿，该股报57.00美元/股，成交量9139股，换手率0.03%，振幅5.24%。Belite Bio Inc股票所在的生物技术行业中，整体跌幅为1.89%。其相关个股中，Omega Therapeutics, Inc.、Oramed Pharmaceuticals Inc.、Dominari Holdings Inc.涨幅较大，Lipella Pharmaceuticals Inc.、Ocean Biomedical, Inc.、Dominari Holdings Inc.较为活跃，换手率分别为3036.61%、1356.45%、446.63%，振幅较大的相关个股有Omega Therapeutics, Inc.、Ocean Biomedical, Inc.、Dominari Holdings Inc.，振幅分别为143.33%、59.46%、58.60%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250212012135961f64d0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250212012135961f64d0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BLTE","BK4007"],"gpt_icon":0}],"profile":{"websiteUrl":"http://investors.belitebio.com","stockEarnings":[{"period":"1week","weight":-0.0492},{"period":"1month","weight":0.2211},{"period":"3month","weight":1.1305},{"period":"6month","weight":1.3613},{"period":"1year","weight":1.2863},{"period":"ytd","weight":1.2588}],"compareEarnings":[{"period":"1week","weight":-0.0042},{"period":"1month","weight":0.0131},{"period":"3month","weight":0.0314},{"period":"6month","weight":0.1394},{"period":"1year","weight":0.1266},{"period":"ytd","weight":0.1615}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Belite Bio, Inc于2018年3月27日在开曼群岛注册成立。该公司是一家临床阶段的生物制药及药物开发公司，专注于针对目前无法治疗的眼部疾病的新疗法，这些疾病涉及有重大未满足医疗需求的视网膜变性，例如（i）萎缩性年龄相关性黄斑变性（AMD），通常称为地理萎缩（GA），或晚期干性AMD，和（ii）常染色体隐性遗传Stargardt病1型，或STGD1，这两种疾病都会导致进行性视力丧失，导致永久性失明。该公司的药物研发管道还包括一种小分子口服复方药物，用于治疗代谢性疾病，如非酒精性脂肪肝、非酒精性脂肪性肝炎、NASH、2型糖尿病、T2D和痛风。","yearOnYearQuotes":[{"month":1,"riseRate":0,"avgChangeRate":-0.046453},{"month":2,"riseRate":0.666667,"avgChangeRate":0.052618},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.036455},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.0153},{"month":5,"riseRate":0.75,"avgChangeRate":0.064631},{"month":6,"riseRate":0.25,"avgChangeRate":0.187208},{"month":7,"riseRate":1,"avgChangeRate":0.228556},{"month":8,"riseRate":0.25,"avgChangeRate":0.09699},{"month":9,"riseRate":0.5,"avgChangeRate":0.027284},{"month":10,"riseRate":0.75,"avgChangeRate":0.224047},{"month":11,"riseRate":0.75,"avgChangeRate":0.12408},{"month":12,"riseRate":0.5,"avgChangeRate":0.010468}],"exchange":"NASDAQ","name":"Belite Bio, Inc.","nameEN":"Belite Bio, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Belite Bio, Inc.(BLTE)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Belite Bio, Inc.(BLTE)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Belite Bio, Inc.,BLTE,Belite Bio, Inc.股票,Belite Bio, Inc.股票老虎,Belite Bio, Inc.股票老虎国际,Belite Bio, Inc.行情,Belite Bio, Inc.股票行情,Belite Bio, Inc.股价,Belite Bio, Inc.股市,Belite Bio, Inc.股票价格,Belite Bio, Inc.股票交易,Belite Bio, Inc.股票购买,Belite Bio, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Belite Bio, Inc.(BLTE)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Belite Bio, Inc.(BLTE)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}